Catabasis Pharmaceuticals, Inc.
EDASALONEXENT DOSING REGIMEN FOR TREATING MUSCULAR DYSTROPHY
Last updated:
Abstract:
The invention provides methods and compositions for treating a muscular dystrophy, e.g., Duchenne muscular dystrophy (DMD), in a subject, with a fatty acid acetylated salicylate, e.g., edasalonexent, effective to achieve a threshold plasma concentration of the fatty acid acetylated salicylate in the subject, e.g., a threshold plasma concentration of at least about 20 ng/ml for least 12 hours in a 24 hour period.
Status:
Application
Type:
Utility
Filling date:
5 Nov 2018
Issue date:
28 Jan 2021